Alimera up 10% on ILUVIEN regulatory filing in Canada

• Thinly traded nano cap Alimera Sciences (NASDAQ:ALIM +10.4%) perks up on almost a 7x surge in volume in response to the news that distribution partner Knight Therapeutics has filed a New Drug Submission in Canada seeking approval of ILUVIEN (fluocinolone acetonide intravitreal implant), a sustained-release implant approved in the U.S. to treat diabetic macular edema.
• Knight has exclusive distribution rights to the product in Canada under a July 2015 agreement with Alimera.